Trials / Completed
CompletedNCT02367638
Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults
A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- All
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MG1111 | Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection |
| BIOLOGICAL | VARIVAX | VARIVAX is administered by subcutaneous injection |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-07-01
- First posted
- 2015-02-20
- Last updated
- 2017-04-27
Source: ClinicalTrials.gov record NCT02367638. Inclusion in this directory is not an endorsement.